208 related articles for article (PubMed ID: 2122928)
21. Clinical and biological effects of gamma interferon and the combination of gamma interferon and interleukin-2 after autologous bone marrow transplantation.
Vey N; Viens P; Fossat C; Olive D; Sainty D; Baume D; Stoppa AM; Bouabdallah R; Brandely M; Gastaut JA; Maraninchi D; Blaise D
Eur Cytokine Netw; 1997 Dec; 8(4):389-94. PubMed ID: 9459619
[TBL] [Abstract][Full Text] [Related]
22. Interleukin-2 in association with increasing doses of interferon-gamma in patients with advanced cancer.
Viens P; Blaise D; Stoppa AM; Brandely M; Baume D; Olive D; Resbeut M; Delpero JR; Lopez M; Aubert C
J Immunother (1991); 1992 Apr; 11(3):218-24. PubMed ID: 1515426
[TBL] [Abstract][Full Text] [Related]
23. Long-term treatment with low doses of interleukin-2 and interferon-alpha: immunological effects in advanced renal cell cancer.
Pavone L; Andrulli S; Santi R; Majori M; Buzio C
Cancer Immunol Immunother; 2001 Apr; 50(2):82-6. PubMed ID: 11401029
[TBL] [Abstract][Full Text] [Related]
24. Phase 1 clinical trial of recombinant interleukin-2: a comparison of bolus and continuous intravenous infusion.
Kohler PC; Hank JA; Moore KH; Storer B; Bechhofer R; Hong R; Sondel PM
Cancer Invest; 1989; 7(3):213-23. PubMed ID: 2790538
[TBL] [Abstract][Full Text] [Related]
25. Hepatic and serologic toxicity of systemic interleukin-2 and/or interferon-alpha. Evidence of a risk-benefit advantage of subcutaneous therapy.
Schomburg A; Kirchner H; Lopez-Hänninen E; Menzel T; Rudolph P; Körfer A; Fenner M; Poliwoda H; Atzpodien J
Am J Clin Oncol; 1994 Jun; 17(3):199-209. PubMed ID: 7910716
[TBL] [Abstract][Full Text] [Related]
26. Natural killer cell cytotoxicity is enhanced by very low doses of rIL-2 and rIFN-alpha in patients with renal cell carcinoma.
Pavone L; Fanti G; Bongiovanni C; Goldoni M; Alberici F; Bonomini S; Cristinelli L; Buzio C
Med Oncol; 2009; 26(1):38-44. PubMed ID: 18516705
[TBL] [Abstract][Full Text] [Related]
27. Extended continuous infusion low-dose recombinant interleukin-2 in advanced cancer: prolonged immunomodulation without significant toxicity.
Caligiuri MA; Murray C; Soiffer RJ; Klumpp TR; Seiden M; Cochran K; Cameron C; Ish C; Buchanan L; Perillo D
J Clin Oncol; 1991 Dec; 9(12):2110-9. PubMed ID: 1960552
[TBL] [Abstract][Full Text] [Related]
28. Lysis of human solid tumor cells by lymphokine-activated natural killer cells.
Itoh K; Tilden AB; Balch CM
J Immunol; 1986 May; 136(10):3910-5. PubMed ID: 3084648
[TBL] [Abstract][Full Text] [Related]
29. Immunologic and clinical modifications following low-dose subcutaneous administration of rIL-2 in non-Hodgkin's lymphoma patients after autologous bone marrow transplantation.
Lauria F; Raspadori D; Ventura MA; Rondelli D; Zinzani PL; Gherlinzoni F; Miggiano MC; Fiacchini M; Rosti G; Rizzi S; Tura S
Bone Marrow Transplant; 1996 Jul; 18(1):79-85. PubMed ID: 8831999
[TBL] [Abstract][Full Text] [Related]
30. Changes in lymphocyte subsets following multiple administration of recombinant interleukin-2 plus recombinant interferon-beta or -gamma in tumor-bearing mice.
Iigo M; Nishikata K; Nakajima Y; Moriyama M
Jpn J Cancer Res; 1989 Jun; 80(6):554-61. PubMed ID: 2527216
[TBL] [Abstract][Full Text] [Related]
31. A phase I clinical trial of recombinant interleukin-2 by periodic 24-hour intravenous infusions.
Creekmore SP; Harris JE; Ellis TM; Braun DP; Cohen II; Bhoopalam N; Jassak PF; Cahill MA; Canzoneri CL; Fisher RI
J Clin Oncol; 1989 Feb; 7(2):276-84. PubMed ID: 2783732
[TBL] [Abstract][Full Text] [Related]
32. Immunological evaluation of pediatric cancer patients receiving recombinant interleukin-2 in a phase I trial.
Truitt RL; Piaskowski V; Kirchner P; McOlash L; Camitta BM; Casper JT
J Immunother (1991); 1992 May; 11(4):274-85. PubMed ID: 1599913
[TBL] [Abstract][Full Text] [Related]
33. Low-dose natural interleukin-2 and recombinant interferon-gamma following autologous bone marrow grafts in pediatric patients with high-risk acute leukemia.
Baumgarten E; Schmid H; Pohl U; Brzoska J; Linderkamp C; Siegert W; Henze G
Leukemia; 1994 May; 8(5):850-5. PubMed ID: 8182941
[TBL] [Abstract][Full Text] [Related]
34. Recombinant interleukin-2 (rIL-2) after autologous bone marrow transplantation (BMT): a pilot study in 19 patients.
Blaise D; Viens P; Olive D; Stoppa AM; Gabert J; Pourreau CN; Attal M; Gaspard MH; Mannoni P; Jasmin C
Eur Cytokine Netw; 1991; 2(2):121-9. PubMed ID: 1813015
[TBL] [Abstract][Full Text] [Related]
35. Generation of activated killer (AK) cells by recombinant interleukin 2 (rIL 2) in collaboration with interferon-gamma (IFN-gamma).
Itoh K; Shiiba K; Shimizu Y; Suzuki R; Kumagai K
J Immunol; 1985 May; 134(5):3124-9. PubMed ID: 2984283
[TBL] [Abstract][Full Text] [Related]
36. Lack of correlation between peripheral blood lymphokine-activated killer (LAK) cell function and clinical response in patients with advanced malignant melanoma receiving recombinant interleukin 2.
Ghosh AK; Dazzi H; Thatcher N; Moore M
Int J Cancer; 1989 Mar; 43(3):410-4. PubMed ID: 2784419
[TBL] [Abstract][Full Text] [Related]
37. A direct comparison of immunological and clinical effects of interleukin 2 with and without interferon-alpha in humans.
Schiller JH; Hank J; Storer B; Borchert AA; Moore KH; Albertini M; Bechhofer R; Wesley O; Brown RR; Bastin AM
Cancer Res; 1993 Mar; 53(6):1286-92. PubMed ID: 8443808
[TBL] [Abstract][Full Text] [Related]
38. Phenotypic and functional modulation of interleukin-2-activated peripheral blood mononuclear cells by anti-CD3 and anti-CD28 antibody.
Yoshino I; Yano T; Miyamoto M; Sugimachi K; Kimura G; Nomoto K
Lymphokine Cytokine Res; 1993 Aug; 12(4):191-6. PubMed ID: 8218591
[TBL] [Abstract][Full Text] [Related]
39. Immunological and clinical effects of intramuscular rIFN alpha-2a and low dose subcutaneous rIL-2 in patients with advanced malignant melanoma.
Castello G; Comella P; Manzo T; Napolitano M; Parziale AP; Galati MG; Daponte A; Casaretti R; Celentano E; Comella G
Melanoma Res; 1993 Feb; 3(1):43-9. PubMed ID: 8471836
[TBL] [Abstract][Full Text] [Related]
40. Low-dose recombinant interleukin-2 therapy in advanced multiple myeloma.
Peest D; Leo R; Bloche S; Hein R; Stannat-Kiessling S; Tschechne B; Fett W; Harms P; Hoffmann L; Bartl R
Br J Haematol; 1995 Feb; 89(2):328-37. PubMed ID: 7873383
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
